Company Focus
Amgen
Latest Amgen News
Biotechnology
US pharma major Eli Lilly has launched Lormalzi (donanemab) in India, bringing one of the world’s newest Alzheimer’s disease therapies into a market with rapidly rising dementia rates but limited specialist infrastructure. 14 May 2026
Related News
Insights
Company Spotlight
A Maryland-based oncology-focused biotech developing antibody-based therapeutics using proprietary bispecific and ADC platforms, with one approved PD-1 inhibitor and a Gilead-partnered bispecific CD123xCD3 program in clinical development.
Latest News & Features of interest to Amgen
Pharmaceutical
US regulator the Food and Drug Administration has granted accelerated approval to Beqalzi (sonrotoclax), giving BeOne Medicines its first regulatory clearance for the next-generation BCL-2 inhibitor. 14 May 2026
Pharmaceutical
Germany’s Merck KGaA has reported first-quarter 2026 results ahead of analyst expectations and raised its full-year guidance, driven by strong momentum in its Life Science business and resilience in Healthcare. 13 May 2026
Biotechnology
Servier Ventures, the VC fund created by the French drugmaker, has selected Cytospire Therapeutics for its first investment. 13 May 2026
Biotechnology
Boehringer Ingelheim and US clinical-stage drug developer Immunitas Therapeutics have announced a global licensing agreement for a pre-clinical antibody program being developed for chronic inflammatory and autoimmune diseases. 13 May 2026
Biotechnology
UK based clinical-stage biotech Artios Pharma announced a clinical trial collaboration and supply agreement with UK pharma major GSK to evaluate alnodesertib, Artios’ ATR inhibitor, in combination with risvutatug rezetecan (also referred to as Ris-Rez). 13 May 2026
Pharmaceutical
Italian drugmaker Recordati reported first-quarter 2026 revenue of 713 million euros ($775 million) on Tuesday, up 5% year-on-year, while diluted earnings per share rose 22% to 0.73 euros, driven by continued growth in its rare diseases business. 13 May 2026
Pharmaceutical
US biotech Rigel Pharmaceuticals is betting heavily on the newly-approved breast cancer therapy Veppanu (vepdegestrant), agreeing to pay Pfizer and Arvinas up to $405 million for global rights to the medicine in a deal designed to reshape the company’s growth trajectory. 13 May 2026
Pharmaceutical
Hengrui Pharma's Hong Kong-listed shares surged significantly to around HK$76.00 - up over 13% - after the company announced a massive licensing accord with Bristol-Myers Squibb. 12 May 2026
Pharmaceutical
Germany’s Bayer has reported a solid start to 2026, with first-quarter earnings beating analyst expectations, driven primarily by strong performance in its Crop Science division. 12 May 2026
Biotechnology
San Diego, USA-based precision oncology company Erasca, which is developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, yesterday announced a clinical trial collaboration and supply agreement (CTCSA) with Merck & Co. 12 May 2026
Latest In Brief for Amgen
Biotechnology
US Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a US appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular dystrophy (DMD) treatment, according to a Reuters report. 23 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze